Navigation Links
Asmacure Ltee to Present at the 2011 BioPharm America Conference
Date:9/1/2011

QUEBEC CITY, Sept. 1, 2011 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, announced today that CEO Martin Driscoll will present at the 2011 BioPharm America Conference taking place September 7-9.  Mr. Driscoll will provide an overview of Asmacure's nicotinic acetylcholine receptor technology, with emphasis on the company's lead product in development for the treatment of asthma, ASM-024.  The presentation will be given on Friday, September 9, at 9:00 a.m. EDT in the Hancock room at the Westin Boston Waterfront Hotel in Boston, MA.

About Asmacure Ltee

Asmacure Ltee is a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases.  The company's lead compound, ASM-024, is a novel molecular entity currently in clinical development for the treatment of asthma.  ASM-024 utilizes Asmacure's proprietary technology comprised of nicotinic acetylcholine receptor agonists and is the first nicotinic receptor agonist in the clinic for this indication.  Phase II proof-of-concept studies are ongoing to assess the anti-inflammatory, bronchodilating and bronchoprotective properties of ASM-024 administered by inhalation.  

Asmacure is a privately held company located in Quebec City, Canada.  The major investors in Asmacure include Domain Associates, Fonds Bio-Innovation and Innovatech Quebec.  For more information visit www.asmacure.com

Media Contacts:
Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mielach, amielach@tiberend.com
or
Claire Sojda, csojda@tibere
'/>"/>

SOURCE Asmacure Ltee
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO
2. Verenium to Present at Upcoming Conferences
3. Idenix Pharmaceuticals to Present at Three Upcoming Investor Conferences
4. Hadasit to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13, 2011
5. Auxilium Pharmaceuticals to Present at the Morgan Stanley 2011 Healthcare Conference
6. PAREXEL International to Present at Robert Baird Healthcare Conference and William Blair Emerging Growth Stock Conference
7. Life Technologies to Present at the UBS 2011 Global Life Sciences Conference
8. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
9. Bacterin International to Present at Stifel Nicolaus 2011 Healthcare Conference on September 8, 2011
10. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research Meeting
11. Insmed to Present at 2011 Wedbush Securities Life Sciences Management Access Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
(Date:1/14/2014)... Jan. 14, 2014   Kinaxis ®, provider of RapidResponse ... sales and operations planning ( S&OP ) service, is proud ... , which will be held at the Hilton San Diego ... Kinaxis customer Elisabeth Kaszas , Director of Supply Chain ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed unknowingly ... this time period, doctors did not know that they needed ... death of vulnerable patients. In the same way, medical interns ... unwittingly transmitting herpes viruses to their patients. The CBCD explains. ...
(Date:1/14/2014)... January 14, 2014 Holloway America today ... of material test reports (MTRs) for all pressure vessels ... test results is particularly important for equipment that must ... MTR Library features search functionality that allows authorized users ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... Data Reported by Roche at 69th Scientific Sessions , ... Inc. (Nasdaq: VIAP ), a biotechnology company ... of cardiovascular and metabolic disease, announced today that preclinical ... inhibitors will be presented in a poster presentation at ...
... , Thursday, June 11th, 10:00 a.m. EDT , , ... ) announced today that the Company President and Chief Executive Officer, ... on Thursday, June 11th, 2009 at 10:00 a.m. EDT, to report ... a quarterly update of the Company. , , This call ...
... initial steps towards producing Influenza A (H1N1) VLP vaccine for ... 4 Novavax, Inc. (Nasdaq: NVAX ) and ... National Institute of Allergy and Infectious Diseases (NIAID), National Institutes ... the evaluation of a virus-like particle (VLP) vaccine candidate against ...
Cached Biology Technology:VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 2VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 3VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 4Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results 2Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results 3Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus 2Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus 3Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus 4
(Date:4/23/2014)... Wash. -- Like a hungry diner ripping open a ... into electricity must tear open a hydrogen molecule. Now ... holding onto the two halves of its hydrogen feast. ... how to make the catalyst work better for alternative ... scientists have shown precisely where the hydrogen halves end ...
(Date:4/23/2014)... Putnam Valley, NY. (Apr. 23 2014) ... human neural stem cells (hNSCs) into the brains ... differentiation after 22 and 24 months found that ... months and did not cause tumors. , The ... of Cell Transplantation but is currently ...
(Date:4/23/2014)... evidence of an interaction between prenatal smoking and ... children, especially in girls. , "The interesting issue ... smoking will have behavioral problems. Some might, ... Professor at Sam Houston State University, College of ... "One possible explanation for this is that ...
Breaking Biology News(10 mins):Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Study finds long-term survival of human neural stem cells transplanted into primate brain 2Genetics risk, prenatal smoking may predict behavioral problems 2
... we are strong and healthy and then we weaken and die ... about. But, in nature, the phenomenon of ageing shows an unexpected ... The University of Southern Denmark. Not all species weaken ... get stronger and less likely to die with age, while others ...
... The addition of a monoclonal antibody called gemtuzumab combined ... the risk of relapse and increase rates of disease-free ... Post-treatment relapse rates are a major indicator of potential ... The study (abstract #355) evaluated a total of 1,022 ...
... EPA grant, NJIT established its Technical Assistance to Brownfield ... allow NJIT to continue to provide communities with scientific, ... Specifically, the grant allows the NJIT TAB team to ... Mid-Atlantic region. NJIT TAB is comprised of planners, environmental ...
Cached Biology News:Surprising diversity in aging revealed in nature 2Surprising diversity in aging revealed in nature 3Targeted treatment can significantly reduce relapse in children with AML leukemia 2EPA awards $1 million grant to NJIT's Brownfield program 2
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
RABBIT ANTI PARATHION...
Recombinant Rhesus Monkey IFN-Alpha...
2,4-Dinitrophenyl hapten is conjugated to BSA (Bovine Serum Albumin) protein through lysine....
Biology Products: